Association between durable response (DR) and overall survival (OS) in patients with unresected stage IIIb-IV melanoma treated with Talimogene Laherparepvec (T-VEC) in the Phase III OPTiM trial. (6th November 2014) - Kaufman, Howard L; Andtbacka, Robert HI; Collichio, Frances A; Wolf, Michael; Li, Ai; Shilkrut, Mark; Puzanov, Igor; Ross, Merrick